HUP0104841A2 - Hatóanyagként NF-kB gátló hatású benzokinonszármazékot vagy kondenzált pirimidinszármazékot tartalmazó gyógyszerkészítmények szívizomgyulladás, dilatatív kardiomiopátia vagy szívelégtelenség kezelésére - Google Patents
Hatóanyagként NF-kB gátló hatású benzokinonszármazékot vagy kondenzált pirimidinszármazékot tartalmazó gyógyszerkészítmények szívizomgyulladás, dilatatív kardiomiopátia vagy szívelégtelenség kezeléséreInfo
- Publication number
- HUP0104841A2 HUP0104841A2 HU0104841A HUP0104841A HUP0104841A2 HU P0104841 A2 HUP0104841 A2 HU P0104841A2 HU 0104841 A HU0104841 A HU 0104841A HU P0104841 A HUP0104841 A HU P0104841A HU P0104841 A2 HUP0104841 A2 HU P0104841A2
- Authority
- HU
- Hungary
- Prior art keywords
- active ingredient
- hydrogen atom
- myocarditis
- dilated cardiomyopathy
- treating
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title abstract 4
- 206010056370 Congestive cardiomyopathy Diseases 0.000 title abstract 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 208000009525 Myocarditis Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 102000003945 NF-kappa B Human genes 0.000 abstract 3
- 108010057466 NF-kappa B Proteins 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000004057 1,4-benzoquinones Chemical class 0.000 abstract 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical group C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical group 0.000 abstract 1
- 150000001555 benzenes Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical group 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000687 hydroquinonyl group Chemical group C1(O)=C(C=C(O)C=C1)* 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 150000002468 indanes Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A találmány tárgyát hatóanyagként NF-kB inhibitort tartalmazó,szívizomgyulladás, dilatatív kardiomiopátia és szívelégtelenségkezelésére és megelőzésére szolgáló gyógyszervegyületek képezik. Atalálmány szerinti gyógyszerkészítményben NF-kB gátló hatóanyagkéntolyan (I) általános képletű benzokinonszármazékot, annak hidrokinonformáját vagy gyógyszerészetileg elfogadható sóját alkalmazzák,amelynek képletében R1, R2 és R3 jelentése egymástól függetlenülhidrogénatom, alkil- vagy alkoxicsoport; R4 jelentése hidrogénatom,hidroxi-metil-, alkil- vagy adott esetben észterezett vagy amidezettkarboxilcsoport; Z jelentése szubsztituált benzolgyűrű; és n jelentése0 és 6 közötti egész szám. A találmány szerinti gyógyszerkészítménybenNF-kB gátló hatóanyagként alkalmazható még olyan (XVII) általánosképletű indánszármazék, vagy gyógyászatilag elfogadható sója, amelynekképletében R1 jelentése hidrogénatom vagy alkilcsoport; és R2jelentése hidrogénatom, éter-, észter-, karboxil-, amid- vagyalkenilcsoport; a pirimidinnel kondenzált rész valamely heterociklusosgyűrű. Ó
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26468299 | 1999-09-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0104841A2 true HUP0104841A2 (hu) | 2002-05-29 |
HUP0104841A3 HUP0104841A3 (en) | 2002-07-29 |
Family
ID=17406743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0104841A HUP0104841A3 (en) | 1999-09-17 | 2000-09-18 | Medicaments containing benzoquinone- or condensed pyrimidine derivatives as active ingredient for treating of myocarditis, dilated cardiomyopathy and cardiac insufficiency |
Country Status (9)
Country | Link |
---|---|
US (1) | US6703421B1 (hu) |
EP (1) | EP1132093A4 (hu) |
JP (1) | JP4660045B2 (hu) |
KR (1) | KR100704152B1 (hu) |
CN (1) | CN1212861C (hu) |
AU (1) | AU7315400A (hu) |
CA (1) | CA2350992C (hu) |
HU (1) | HUP0104841A3 (hu) |
WO (1) | WO2001021206A1 (hu) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE317691T1 (de) * | 1998-03-20 | 2006-03-15 | Daiichi Asubio Pharma Co Ltd | Benzochinonderivate enthaltende hemmer von nf-kb |
US20030186963A1 (en) | 2001-09-14 | 2003-10-02 | Dorwald Florencio Zaragoza | Substituted piperidines |
HUP0303760A2 (hu) | 2001-09-17 | 2004-03-01 | Daiichi Suntory Biomedical Research Co., Ltd. | AZ NF-kB faktort gátló szubsztituált benzoesavszármazékok és ezeket tartalmazó gyógyszerkészítmények |
US7064135B2 (en) | 2001-10-12 | 2006-06-20 | Novo Nordisk Inc. | Substituted piperidines |
WO2003031432A1 (en) | 2001-10-12 | 2003-04-17 | Novo Nordisk A/S | Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor |
WO2003053425A1 (en) * | 2001-12-10 | 2003-07-03 | Yansheng Du | Treatment of neurodegenerative and cardiovascular disorders |
US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
CN100418532C (zh) * | 2005-06-17 | 2008-09-17 | 吕志民 | 治疗多种疾病的NF-κB化合物抑制剂 |
EP1971611B1 (en) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Anti-viral compounds |
AU2006330924B2 (en) * | 2005-12-21 | 2012-03-15 | Abbvie Inc. | Anti-viral compounds |
DE102005061170A1 (de) | 2005-12-21 | 2007-07-05 | Bayer Healthcare Ag | Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung |
DE102005061171A1 (de) | 2005-12-21 | 2007-07-05 | Bayer Healthcare Ag | Neue, cyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung |
WO2008021456A2 (en) * | 2006-08-16 | 2008-02-21 | Cytovia, Inc. | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
TWI399380B (zh) * | 2006-12-20 | 2013-06-21 | Abbott Lab | 抗病毒化合物 |
DE102007019691A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
DE102007019690A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
DE102007027799A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte Furopyrimidine und ihre Verwendung |
CN101422462B (zh) * | 2008-12-18 | 2011-08-17 | 中国医学科学院实验动物研究所 | 磷酸川芎嗪作为制备治疗扩张型心肌病的药物中的应用 |
CN109384711A (zh) * | 2017-08-07 | 2019-02-26 | 南京柯菲平盛辉制药有限公司 | 一类茚满-5-甲酰胺RORγ调节剂及其用途 |
WO2022238507A1 (en) * | 2021-05-11 | 2022-11-17 | Awakn Ls Europe Holdings Limited | Therapeutic aminoindane compounds and compositions |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR206505A1 (es) | 1972-09-18 | 1976-07-30 | Christiaens Sa A | Procedimiento para obtener nuevos derivados de n-fenil-n-aminoalquil-2-aminoindano |
JPS58177934A (ja) | 1982-04-13 | 1983-10-18 | Takeda Chem Ind Ltd | ベンゾキノン誘導体 |
US5220042A (en) * | 1984-01-26 | 1993-06-15 | Otsuka Pharmaceutical Co., Ltd. | 1,4-benzoquinone derivatives and benzene derivatives, and process for preparing the same |
MX9203040A (es) * | 1984-08-01 | 1992-07-31 | Takeda Chemical Industries Ltd | Derivados de quinona y composicion farmaceutica que los contiene. |
JP2506337B2 (ja) * | 1986-06-06 | 1996-06-12 | サントリー株式会社 | フエニルメチルベンゾキノン誘導体 |
DE3707358A1 (de) * | 1987-03-07 | 1988-09-15 | Basf Ag | Substituierte 2,3-epoxy-5-cyclohexenonderivate und diese enthaltende fungizide und herbizide |
JP3042547B2 (ja) * | 1990-05-11 | 2000-05-15 | サントリー株式会社 | ベンゾフラン誘導体及びそれを含む虚血による器質性又は機能性障害治療剤 |
JP3016625B2 (ja) * | 1990-06-01 | 2000-03-06 | サントリー株式会社 | フェノキシ酢酸誘導体及びそれを含む虚血による器質性又は機能性障害治療剤 |
ES2285712T3 (es) * | 1995-05-12 | 2007-11-16 | Anges Mg, Inc. | Medicamento para la terapia y profilaxis de varias enfermedades relacionadas con nf-kappa b. |
CA2230896A1 (en) * | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
AU726522B2 (en) | 1995-09-01 | 2000-11-09 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
JPH09227561A (ja) * | 1996-02-21 | 1997-09-02 | Tanabe Seiyaku Co Ltd | キサンチン誘導体 |
GB9604361D0 (en) * | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
JP2000511173A (ja) * | 1996-05-27 | 2000-08-29 | 藤沢薬品工業株式会社 | 一酸化窒素産生阻害剤としての新規なインドリルおよびベンゾフラニルカルボキサミド |
JPH1087491A (ja) * | 1996-07-26 | 1998-04-07 | Asahi Chem Ind Co Ltd | 転写調節因子阻害剤 |
JP3843400B2 (ja) * | 1996-09-19 | 2006-11-08 | 裕 尾崎 | アルキル一置換ハイドロキノン類の製造方法 |
AU2662899A (en) * | 1998-02-13 | 1999-08-30 | Medinox, Inc. | Methods for the controlled delivery of carbon disulfide for the treatment of inflammatory conditions |
US6617171B2 (en) | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
ATE317691T1 (de) * | 1998-03-20 | 2006-03-15 | Daiichi Asubio Pharma Co Ltd | Benzochinonderivate enthaltende hemmer von nf-kb |
DE69917201T2 (de) * | 1998-07-22 | 2005-05-04 | Daiichi Suntory Pharma Co., Ltd. | Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten |
-
2000
- 2000-09-18 WO PCT/JP2000/006364 patent/WO2001021206A1/ja active Application Filing
- 2000-09-18 JP JP2001524630A patent/JP4660045B2/ja not_active Expired - Lifetime
- 2000-09-18 AU AU73154/00A patent/AU7315400A/en not_active Abandoned
- 2000-09-18 HU HU0104841A patent/HUP0104841A3/hu unknown
- 2000-09-18 CA CA002350992A patent/CA2350992C/en not_active Expired - Fee Related
- 2000-09-18 KR KR1020017006196A patent/KR100704152B1/ko not_active IP Right Cessation
- 2000-09-18 CN CNB00802443XA patent/CN1212861C/zh not_active Expired - Fee Related
- 2000-09-18 US US09/856,072 patent/US6703421B1/en not_active Expired - Lifetime
- 2000-09-18 EP EP00961066A patent/EP1132093A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN1335777A (zh) | 2002-02-13 |
US6703421B1 (en) | 2004-03-09 |
CA2350992C (en) | 2009-06-23 |
KR100704152B1 (ko) | 2007-04-09 |
KR20010086037A (ko) | 2001-09-07 |
CN1212861C (zh) | 2005-08-03 |
CA2350992A1 (en) | 2001-03-29 |
AU7315400A (en) | 2001-04-24 |
JP4660045B2 (ja) | 2011-03-30 |
EP1132093A1 (en) | 2001-09-12 |
WO2001021206A1 (fr) | 2001-03-29 |
EP1132093A4 (en) | 2006-04-19 |
HUP0104841A3 (en) | 2002-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0104841A2 (hu) | Hatóanyagként NF-kB gátló hatású benzokinonszármazékot vagy kondenzált pirimidinszármazékot tartalmazó gyógyszerkészítmények szívizomgyulladás, dilatatív kardiomiopátia vagy szívelégtelenség kezelésére | |
GEP20053619B (en) | Pyrazole Derivatives for Treating HIV | |
NO20050016L (no) | Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen | |
DE69032414D1 (de) | Diphenylmethane derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen | |
CA2120424A1 (en) | Anti-osteopathic composition | |
KR970701698A (ko) | 프로스타글란딘 i₂작용물질로서의 나프탈렌 유도체(naphthalene derivatives as prostaglandin i₂agonists) | |
RU95102778A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен | |
HUP0400710A2 (hu) | Tioéter helyettesítővel helyettesített imidazokinolinszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
NZ337118A (en) | 3-piperidyl-4-oxoquinazoline derivatives and pharmaceutical compositions comprising the same useful in treating or preventing arteriosclerotic and/or hyper-lipemia disease, pancreatitis, obesity, hypercholesterolemia and hypertriglyceridemia. | |
HUP0002440A2 (hu) | Savas lipofil vegyületeket tartalmazó gyógyászati készítmény ön-emulgeáló formában | |
EA200101077A1 (ru) | Композиция для профилактики или лечения слабоумия, включающая производное гидроксикоричной кислоты или экстракт растения рода angelicae, содержащий его | |
CA2302568A1 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
HUP9700005A2 (hu) | 2-Ureido-benzamid-származékok és ilyeneket hatóanyagként tartalmazó gyógyszerkészítmények | |
AU1466295A (en) | Amino acid derivatives and their use as phospholipase a2 inhibitors | |
EE9900044A (et) | Farmatseutilised tooted veresoonte endoteelirakkude kahjustuste tagajärjel tekkinud haiguste raviks ja vältimiseks | |
PT911026E (pt) | Derivados da creatina para a asma | |
JP3490114B2 (ja) | 軟骨保護剤 | |
ITMI922742A1 (it) | Composti ad attivita' terapeutica utili per il trattamento di malattie connesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. | |
HUP0303353A2 (hu) | Profilaktikus és terápiás szer diabeteses komplikációkhoz | |
HUP0203212A2 (hu) | Integrin inhibitorok, eljárás ezek előállítására, alkalmazásuk gyógyszerkészítmények előállítására és a készítmények | |
AR016212A1 (es) | Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas | |
EA200600022A1 (ru) | Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций | |
DE69713648D1 (de) | Benzopyranderivate und ihre Verwendung zur Behandlung von Herzkrankheiten | |
DE69318715D1 (de) | Pharmakologisch aktive alpha-(tertiär-aminoethyl)-phenylmethanol-derivate | |
FR2824829B1 (fr) | Nouveaux derives de dihydroimidazo [5,1-a]-beta-carboline, leur procede de preparation et leur application a titre de medicament |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |